natgillin/translations-raw huggingface dataset:
Onbrez Breezhaler contains lactose
Zdravilo Onbrez Breezhaler vsebuje laktozo
Always use the new Onbrez Breezhaler inhaler that comes with your new pack.
Vedno uporabljajte samo inhalator Onbrez Breezhaler, ki je priložen novemu pakiranju.
Show the pack of Onbrez Breezhaler.
Tam pokažite škatlo z zdravilom Onbrez Breezhaler.
The Onbrez Breezhaler inhaler provided with each new prescription should be used.
Vedno je treba uporabiti inhalator Onbrez Breezhaler, ki je priložen novemu pakiranju zdravila.
Never take the Onbrez Breezhaler inhaler apart.
Inhalatorja Onbrez Breezhaler nikoli ne razstavljajte.
How to use Onbrez Breezhaler
Kako uporabljati zdravilo Onbrez Breezhaler
Always keep the Onbrez Breezhaler inhaler and capsules in a dry place.
Pazite, da bodo inhalator in kapsule Onbrez Breezhaler vedno na suhem.
Onbrez Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar.
Kapsule Onbrez Breezhaler 150 mikrogramov imajo nad črno črto s črno natisnjeno oznako
Onbrez Breezhaler 300 microgram inhalation powder, hard capsules
Onbrez Breezhaler 300 mikrogramov prašek za inhaliranje, trde kapsule
Onbrez Breezhaler 150 microgram inhalation powder, hard capsules
Onbrez Breezhaler 150 mikrogramov prašek za inhaliranje, trde kapsule
Onbrez Breezhaler 300 microgram inhalation powder, hard capsules indacaterol
Onbrez Breezhaler 300 mikrogramov prašek za inhaliranje, trde kapsule indakaterol
Other medicines and Onbrez Breezhaler
Shranjevanje zdravila Onbrez Breezhaler
Onbrez Breezhaler 150 microgram inhalation powder, hard capsules indacaterol
Onbrez Breezhaler 150 mikrogramov prašek za inhaliranje, trde kapsule indakaterol
• When you start a new pack, only use the new Onbrez Breezhaler inhaler that is supplied in the pack.
• Ko odprete novo škatlo z zdravilom, začnite uporabljati tudi nov inhalator Onbrez Breezhaler,
What Onbrez Breezhaler is
Kaj je zdravilo Onbrez Breezhaler
Do not swallow Onbrez Breezhaler capsules.
Kapsul Onbrez Breezhaler ne smete pogoltniti.
Breezhaler capsules with any other inhaler, and do not use Onbrez Breezhaler inhaler to take any other capsule medicine.
Breezhaler pa ne uporabljajte za inhaliranje drugih zdravil iz kapsul.
• itching/rash
• srbenje/izpuščaj
This means that Ontruzant is similar to another biological medicine (the ‘reference medicine') that is already authorised in the European Union (EU).
To pomeni, da je podobno biološkemu zdravilu (t. i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
The full EPAR for Ontruzant can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ontruzant je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What is Ontruzant and what is it used for?
Kaj je zdravilo Ontruzant in za kaj se uporablja?
What measures are being taken to ensure the safe and effective use of Ontruzant?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ontruzant?
Patients who tolerate the first 90-minute infusion can receive subsequent infusions over 30 minutes.
Bolniki, ki dobro prenesejo prvo 90-minutno infundiranje, lahko naslednje infuzije prejmejo v trajanju 30 minut.
Ontruzant can cause cardiotoxicity (harm to the heart), including heart failure (when the heart does not work as well as it should).
Zdravilo Ontruzant lahko povzroča kardiotoksičnost (škoduje srcu), vključno s srčnim popuščanjem (srce ne deluje tako dobro, kot bi moralo).
The most common or serious side effects with Ontruzant are heart problems, reactions related to the Ontruzant infusion, reduced levels of blood cells, especially white blood cells, infections and lung problems.
Najpogostejši ali resni neželeni učinki zdravila Ontruzant so težave s srcem, reakcije, povezane z infuzijo zdravila Ontruzant, zmanjšana količina krvnih celic, zlasti belih krvnih celic, okužbe in težave s pljuči.
It is not intended to provide practical advice on how to use Ontruzant.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
In addition, a study involving 875 patients with early or locally advanced breast cancer looked at the effectiveness of Ontruzant and Herceptin.
V študiji, ki je vključevala 875 bolnikov z zgodnjim ali lokalno napredovalim rakom dojke, so proučevali tudi učinkovitost zdravil Ontruzant in Herceptin.
The infusion can be associated with allergic reactions, so the patient should be monitored during and after the infusion.
Infuzija je lahko povezana z alergijskimi reakcijami, zato je treba bolnika spremljati med infundiranjem in po njem.
This is a summary of the European public assessment report (EPAR) for Ontruzant.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ontruzant.
What benefits of Ontruzant have been shown in studies?
Kakšne koristi je zdravilo Ontruzant izkazalo v študijah?
What are the risks associated with Ontruzant?
Kakšna tveganja so povezana z zdravilom Ontruzant?
Ontruzant is a cancer medicine used to treat the following conditions:
Ontruzant je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje naslednjih bolezni:
Absence of invasive cancer cells was noted in the tissue removed at surgery in 52% of women given Ontruzant and 42% of those given Herceptin, but in the light of all the available information from the study this difference was not assessed to be relevant.
V tkivu, ki so ga odstranili s kirurškim posegom, so opazili odsotnost invazivnih rakavih celic pri 52 % žensk, ki so prejemale zdravilo Ontruzant, in pri 42 % žensk, ki so prejemale zdravilo Herceptin, vendar glede na vse razpoložljive informacije iz študije ta razlika ni bila ocenjena kot pomembna.
It must not be used in patients who have serious breathing problems because of advanced cancer, even when resting, or who need oxygen therapy.
Ne sme se uporabljati pri bolnikih, ki imajo resne težave z dihanjem zaradi napredovalega raka tudi med počitkom, in bolnikih, ki potrebujejo zdravljenje s kisikom.
Ontruzant must not be used in people who are hypersensitive (allergic) to trastuzumab, mouse proteins or to any of the other ingredients.
Zdravila Ontruzant ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) trastuzumab, mišje beljakovine ali na katero koli drugo sestavino zdravila.
It is used on its own in patients in whom previous treatments have failed.
Pri bolnikih, pri katerih je bilo predhodno zdravljenje neuspešno, se uporablja samostojno.
For more information about treatment with Ontruzant, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Ontruzant preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ontruzant have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ontruzant upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Ontruzant has been shown to have a comparable quality, safety and effectiveness to Herceptin.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Ontruzant po kakovosti, varnosti in učinkovitosti primerljivo zdravilu Herceptin.
Why is Ontruzant approved?
Zakaj je bilo zdravilo Ontruzant odobreno?
For tumours that are locally advanced (including those that are inflammatory) or more than 2 cm wide, Ontruzant is used before surgery in combination with chemotherapy and then again after surgery on its own;
Pri lokalno napredovalih tumorjih (vključno z vnetnimi tumorji) ali tumorjih, širših od 2 cm, se zdravilo Ontruzant uporablja pred kirurškim posegom v kombinaciji s kemoterapijo in nato samostojno po posegu;
Other information about Ontruzant
Druge informacije o zdravilu Ontruzant
Ontruzant can only be obtained with a prescription and treatment should be started by a doctor who has experience in the use of cancer medicines.
Predpisovanje in izdaja zdravila Ontruzant je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravili proti raku.
Because Ontruzant is a biosimilar medicine, the studies on effectiveness and safety of trastuzumab carried out with Herceptin do not all need to be repeated for Ontruzant.
Zdravilo Ontruzant je „podobno biološko zdravilo“, zato študij o učinkovitosti in varnosti trastuzumaba, izvedenih z zdravilom Herceptin, z zdravilom Ontruzant ni treba ponavljati.
By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the tumour cells.
Trastuzumab ob vezavi na HER2 aktivira celice imunskega sistema, ki nato uničijo tumorske celice.
• early breast cancer (when the cancer has spread within the breast or to the glands under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable.
• zgodnjega raka dojk (kadar se je rak razširil znotraj dojke ali v podpazdušne žleze, ne pa na druge dele telesa) po kirurškem posegu, kemoterapiji (zdravljenju z zdravili proti raku) in radioterapiji (zdravljenju z obsevanjem), če je smiselno.
The reference medicine for Ontruzant is Herceptin.
Referenčno zdravilo za zdravilo Ontruzant je zdravilo Herceptin.
The study showed that 94% of women given Ontruzant and 93% of those given Herceptin survived without return or worsening of their disease when followed up for around 14 months.
Študija je pokazala, da je po približno 14-mesečnem spremljanju brez ponovitve ali poslabšanja bolezni preživelo 94 % žensk, ki so prejemale zdravilo Ontruzant, in 93 % žensk, ki so prejemale zdravilo Herceptin.
The recommended dose depends on the patient's body weight and depends on the condition to be treated and whether Ontruzant is given weekly or three-weekly.
Priporočeni odmerek je odvisen od telesne mase bolnika, od zdravljene bolezni in od tega, ali se zdravilo Ontruzant daje vsak teden ali vsake tri tedne.
For practical information about using Ontruzant, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Ontruzant naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
• metastatic gastric (stomach) cancer, in combination with cisplatin and either capecitabine or 5‑fluorouracil (other cancer medicines).
• metastatskega raka želodca, in sicer v kombinaciji s cisplatinom in bodisi kapecitabinom ali 5-fluorouracilom (drugima zdraviloma proti raku).
The active substance in Ontruzant, trastuzumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to the HER2 protein, which is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
Zdravilna učinkovina v zdravilu Ontruzant, trastuzumab, je monoklonsko protitelo (vrsta beljakovine), zasnovano za prepoznavo in vezavo na beljakovino HER2, ki je v čezmerno izražena pri približno četrtini primerov raka dojke in petini primerov raka želodca.
HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
HER2 je čezmerno izražena pri približno četrtini rakov dojke in petini rakov želodca.
The women received one or the other trastuzumab medicine before and after surgery, with other cancer medicines and radiotherapy according to standard practice.
Ženske so pred kirurškim posegom in po njem prejemale eno ali drugo zdravilo s trastuzumabom ter druga zdravila za zdravljenje raka in obsevanje v skladu s standardno prakso.
How is Ontruzant used?
Kako se zdravilo Ontruzant uporablja?
On the basis of all the data provided it was concluded that Ontruzant would behave in the same way as Herceptin in its approved indications.
Na podlagi vseh predloženih podatkov so zaključili, da se bo zdravilo Ontruzant pri odobrenih indikacijah vedlo enako kot zdravilo Herceptin.
Ontruzant is a ‘biosimilar medicine'.
Zdravilo Ontruzant je „podobno biološko zdravilo“.
Therefore, the Agency's view was that, as for Herceptin, the benefit outweighs the identified risk and Ontruzant should be given marketing authorisation.
Zato je menila, da enako kot pri zdravilu Herceptin koristi odtehtajo znana tveganja, in priporočila, da se za zdravilo Ontruzant izda dovoljenje za promet.
Studies have also shown that giving Ontruzant produces similar levels of the active substance in the body to giving Herceptin.
Študije so pokazale tudi, da zdravilo Ontruzant vzpostavi podobne ravni zdravilne učinkovine v telesu kot zdravilo Herceptin.
Laboratory studies comparing Ontruzant with Herceptin have shown that the active substance in Ontruzant is highly similar to that in Herceptin in terms of structure, purity and biological activity.
Laboratorijske študije, v katerih so zdravilo Ontruzant primerjali z zdravilom Herceptin, so pokazale, da je zdravilna učinkovina zdravila Ontruzant po zgradbi, čistosti in biološkem delovanju zelo podobna zdravilni učinkovini v zdravilu Herceptin.
Ontruzant can only be used when the cancer has been shown to ‘overexpress HER2': this means that the cancer produces a protein called HER2 in large quantities on the surface of the tumour cells, which makes the tumour cells grow more quickly.
To pomeni, da na površini tumorskih celic v večjih količinah nastaja beljakovina, imenovana HER2, zato tumorske celice hitreje rastejo.
Trastuzumab also stops HER2 producing signals that cause the tumour cells to grow.
S tem prepreči, da bi HER2 tvorila signale, ki spodbujajo rast tumorskih celic.
Ontruzant contains the active substance trastuzumab.
Zdravilo Ontruzant vsebuje zdravilno učinkovino trastuzumab.
How does Ontruzant work?
Kako zdravilo Ontruzant deluje?
Date of first authorisation: 25 May 2000 Date of latest renewal: 25 May 2010
Datum prve odobritve: 25. maj 2000 Datum zadnjega podaljšanja: 25. maj 2010
You must not use PegIntron if any of the conditions above should apply to you, or the child you are caring for.
Zdravila PegIntron ne smete uporabljati, če katero od zgoraj naštetih stanj velja za vas ali otroka, za katerega skrbite.
PegIntron vials are for single use only.
Viale PegIntron so le za enkratno uporabo.
Other medicines and PegIntron Please tell your doctor or pharmacist if you, or the child you are caring for: - are taking or have recently taken any other medicines or vitamins/nutritional supplements, including medicines obtained without a prescription.
Druga zdravila in zdravilo PegIntron Obvestite zdravnika ali farmacevta, če vi ali otrok, za katerega skrbite: - jemljete ali ste pred kratkim jemali katero koli zdravilo ali vitamine/prehranska dopolnila, vključno z zdravili, ki ste jih dobili brez recepta.
PegIntron is to be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Zdravilo PegIntron lahko med nosečnostjo uporabljate le, če potencialne koristi upravičijo potencialno tveganje za plod.
Acceptable baseline values that may be considered as a guideline prior to initiation of PegIntron therapy are:
Sprejemljive začetne vrednosti, ki vam lahko služijo kot smernica pred uvedbo terapije z zdravilom PegIntron, so naslednje:
Treatment with PegIntron in combination with ribavirin was associated with decreases in absolute CD4+ cell counts within the first 4 weeks without a reduction in CD4+ cell percentage.
Zdravljenje z zdravilom PegIntron v kombinaciji z ribavirinom je bilo povezano z zmanjšanjem absolutnega števila celic CD4+ v prvih 4 tednih, brez zmanjšanja odstotka celic CD4+.
While being treated with PegIntron, your doctor may advise to drink extra fluids to help prevent low blood pressure.
Med zdravljenjem z zdravilom PegIntron vam bo zdravnik morda svetoval, da pijte več tekočine, da bi preprečili pojav nizkega krvnega tlaka.
Water for injection and PegIntron powder are provided in separate ampoules.
Voda za injekcije in PegIntron prašek sta na voljo v ločenih ampulah.
No studies have been conducted in juvenile animals to examine the effects of treatment with PegIntron on growth, development, sexual maturation, and behaviour.
Študij pri mladih živalih, pri katerih bi spremljali vpliv zdravljenja z zdravilom PegIntron na rast, razvoj, spolno dozorevanje in obnašanje, niso izvedli.
Due to reports of interferon alpha exacerbating pre-existing psoriatic disease and sarcoidosis, use of PegIntron in patients with psoriasis or sarcoidosis is recommended only if the potential benefit justifies the potential risk.
Zaradi poročil, da lahko interferon alfa poslabša obstoječo psoriazo in sarkoidozo je uporaba zdravila PegIntron pri bolnikih s psoriazo ali sarkoidozo priporočena le, če možne koristi zdravljenja odtehtajo morebitno tveganje.
Important information about some of the ingredients of PegIntron Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorption or sucraseisomaltase insufficiency should not take this medicine.
Pomembne informacije o nekaterih sestavinah zdravila PegIntron Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze in galaktoze ali pomanjkanjem saharaza-izomaltaze ne smejo jemati tega zdravila.
These adverse reactions were common (≥1/100 to < 1/10) in clinical trials in patients treated with PegIntron monotherapy.
Ti neželeni učinki so bili pogosti (≥1/100 do < 1/10) v kliničnih preskušanjih pri bolnikih, zdravljenih z zdravilom PegIntron v monoterapiji.
Patients may self-inject PegIntron if their physician determines that it is appropriate and with medical follow-up as necessary.
Bolniki si lahko zdravilo PegIntron injicirajo sami, če njihov zdravnik odloči, da je to primerno, in jih po potrebi spremlja.
Prepare the dose by adding water for injection to PegIntron powder just before you intend to inject it and use it immediately.
Odmerek si pripravite z dodajanjem vode za injekcije v PegIntron prašek, tik preden ga nameravate injicirati, in ga uporabite takoj.
Manufacturer SP Labo N.V.
Izdelovalec SP Labo N.V.
Cardiac arrhythmias (primarily supraventricular) usually respond to conventional therapy but may require discontinuation of PegIntron therapy.
Srčne aritmije (predvsem supraventrikularne) se običajno odzovejo na konvencionalno zdravljenje, vendar pa lahko zahtevajo prekinitev zdravljenja z zdravilom PegIntron.
As adherence might be of importance for outcome of therapy, the dose of PegIntron and ribavirin should be kept as close as possible to the recommended standard dose.
Ker je privrženost terapiji pomembna za njeno uspešnost, mora biti odmerek zdravila PegIntron in ribavirina čim bliže standardnemu priporočenemu odmerku.
What PegIntron is and what it is used for
Kaj je zdravilo PegIntron in za kaj ga uporabljamo
No specific antidote for PegIntron is available; therefore, symptomatic treatment and close observation of the patient are recommended in cases of overdose.
Specifičen antidot za zdravilo PegIntron ni na voljo, zato v primeru prevelikega odmerjanja priporočamo simptomatsko zdravljenje in skrbno opazovanje bolnika.
Women of childbearing potential/contraception in males and females PegIntron is recommended for use in fertile women only when they are using effective contraception during the treatment.
Ženske v rodni dobi/kontracepcija pri moških in ženskah Zdravilo PegIntron priporočamo za uporabo pri plodnih ženskah le, če med zdravljenjem uporabljajo učinkovito kontracepcijo.
Table 8 Sustained virological response (% patients HCV negative) PegIntron monotherapy
Preglednica 8 Trajni virološki odziv (% HCV negativnih bolnikov) PegIntron monoterapija
What you need to know before you use PegIntron
Kaj morate vedeti, preden boste uporabili zdravilo PegIntron
PegIntron increases the risk of hepatic decompensation and death in patients with cirrhosis.
Zdravilo PegIntron poveča tveganje za jetrno dekompenzacijo in smrt pri bolnikih s cirozo.
In Study 1 (see section 5.1), decrease in absolute neutrophil count levels below 500 cells/mm 3 was observed in 4 %
V študiji 1 (glejte poglavje 5.1) so opazili zmanjšanje absolutnega števila nevtrofilcev pod 500 celic/mm
This medicine, when given alone, is usually given at a dose of 0.5 or 1.0 microgram per kilogram of body weight once a week, for 6 months to 1 year.
Kadar se to zdravilo uporablja samostojno, je odmerek običajno 0,5 ali 1,0 mikrogram na kilogram telesne mase enkrat na teden, 6 mesecev do 1 leto.
Use in adults - PegIntron alone
Uporaba pri odraslih - zdravilo PegIntron samo
The potential interaction of peginterferon alfa-2b (PegIntron) on substrates of metabolic enzymes was evaluated in 3 multiple-dose clinical pharmacology studies.
Morebitno medsebojno delovanje peginterferona alfa-2b (zdravila PegIntron) in substratov metabolnih encimov so ocenili v 3 kliničnih farmakoloških študijah večkratnih odmerkov.
- Remove the protective cap from the PegIntron vial.
- Odstranite zaščitni pokrovček z viale zdravila PegIntron.
If you forget to take PegIntron
Če ste pozabili vzeti zdravilo PegIntron
PegIntron is likely to also cause this effect.
Tudi zdravilo PegIntron ima verjetno enak učinek.
The side effect may develop at various time points during treatment, typically several months after starting treatment with PegIntron.
Neželeni učinek se lahko pojavi ob različnih časovnih točkah zdravljenja, običajno nekaj mesecev po začetku zdravljenja z zdravilom PegIntron.
Anaemia (hemoglobin < 9.4 g/dl) was reported in 12 % (23/194) of patients treated with PegIntron in combination with ribavirin.
O anemiji (hemoglobin < 9,4 g/dl) so poročali pri 12 % (23/194) bolnikov, zdravljenih z zdravilom PegIntron v kombinaciji z ribavirinom.
dizziness), decrease in certain white blood cells (that makes you more susceptible to different infections), - pain in joints and muscles, muscle and bone pain.
zmanjšanje nekaterih belih krvnih celic (ki vas naredi bolj dovzetne za različne okužbe), - bolečine v sklepih in mišicah, mišične in kostne bolečine.
Therefore, the combination of PegIntron with telbivudine is contraindicated (see section 4.3).
Kombinacija zdravila PegIntron in telbivudina je zato kontraindicirana (glejte poglavje 4.3).
Do not inject PegIntron into an area where the skin is irritated, red, bruised, infected, or has scars, stretch marks, or lumps.
Zdravila PegIntron ne injicirajte v predele, kjer je koža razdražena, pordela, podpluta, okužena, ali kjer so brazgotine, proge (strije) ali bule.
** For patients > 120 kg, the PegIntron dose should be calculated based on the individual patient weight.
** Za bolnike, ki so težji od 120 kg, mora biti odmerek izračunan individualno glede na telesno maso bolnika.
Mean (SD) PegIntron elimination half-life is approximately 40 hours (13.3 hours), with apparent clearance of 22.0 ml/hr/kg.
Srednja (SD) razpolovna doba eliminacije zdravila PegIntron je približno 40 ur (13,3 ure), navidezni očistek zdravila pa je 22,0 ml/h/kg.
The negative predictive value for sustained response in patients treated with PegIntron in monotherapy was 98 %.
Negativna napovedna vrednost za trajni odziv pri bolnikih, zdravljenih z zdravilom PegIntron v monoterapiji, je bila 98 %.
PegIntron 1.5 micrograms/kg/week in combination with ribavirin capsules.
PegIntron 1,5 mikrogramov/kg/teden v kombinaciji s kapsulami ribavirina.
Patients who develop fatigue, somnolence or confusion during treatment with PegIntron are cautioned to avoid driving or operating machines.
Bolniki, ki postanejo utrujeni, zaspani ali zmedeni med zdravljenjem z zdravilom PegIntron, naj ne vozijo in ne upravljajo strojev.
The use of this medicine in children and adolescents with existence of or history of severe psychiatric conditions is not allowed (see section “Do not use PegIntron” above).
Uporaba tega zdravila pri otrocih in mladostnikih z obstoječo ali s hudo psihično boleznijo v preteklosti ni dovoljena (glejte zgoraj poglavje "Ne uporabljajte zdravila PegIntron").